JP6722293B2 - 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 - Google Patents
終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 Download PDFInfo
- Publication number
- JP6722293B2 JP6722293B2 JP2018543120A JP2018543120A JP6722293B2 JP 6722293 B2 JP6722293 B2 JP 6722293B2 JP 2018543120 A JP2018543120 A JP 2018543120A JP 2018543120 A JP2018543120 A JP 2018543120A JP 6722293 B2 JP6722293 B2 JP 6722293B2
- Authority
- JP
- Japan
- Prior art keywords
- age
- antibody
- seq
- cells
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
である。
1.Gruberらの国際出願公開第WO2009/143411号(2009年11月26日)。
2.Bucalaらの米国特許第5,702,704号(1997年12月30日発行)。
3.Al−Abedらの米国特許第6,380,165号(2002年4月30日発行)。
4.Wrightらの米国特許第6,387,373号(2002年5月14日発行)。
5.Vanlerbergheらの米国特許第4,217,344号(1980年8月12日発行)。
6.Wallachの米国特許第4,917,951号(1990年4月17日発行)。
7.Wallachの米国特許第4,911,928号(1990年3月27日発行)。
8.Smithらの米国特許出願公開第US2010/226932号(2010年9月9日)。
9.Ando K,et al.,“Membrane Proteins of Human Erythrocytes Are Modified by Advanced Glycation End Products During Aging in the Circulation,”Biochemical and Biophysical Research Communications,Vol.258,123−27(1999)。
10.Lindsey JB,et al.,“Receptor For Advanced Glycation End−Products(RAGE)and soluble RAGE(sRAGE):Cardiovascular Implications,”Diabetes Vascular Disease Research,Vol.6(1),7−14,(2009)。
11.Bierhaus A,“AGEs and their interaction with AGE−receptors in vascular disease and diabetes mellitus. I.The AGE concept,”Cardiovasc Res,Vol.37(3),586−600 (1998)。
12.Meuter A.,et al.“Markers of cellular senescence are elevated in murine blastocysts cultured in vitro:molecular consequences of culture in atmospheric oxygen”J Assist Reprod Genet.2014Aug10.[印刷前オンライン先行公開]。
13.Baker,D.J.et al.,“Clearance of p16Ink4a−positive senescent cells delays ageing−associated disorders”,Nature,vol.479,pp.232−236,(2011)。
14.Jana Hadrabova,et al.“Chicken immunoglobulins for prophylaxis:Effect of inhaled antibodies on inflammatory parameters in rat airways”Journal of Applied Biomedicine(印刷中、2014年5月5日オンライン入手可能)。
15.Vlassara,H.et al.,“High−affinity−receptor−mediated Uptake and Degradation of Glucose−modified Proteins:A Potential Mechanism for the Removal of Senescent Macromolecules”,Proc.Natl.Acad.Sci.USA,Vol.82,5588,5591(1985)。
16.Roll,P.et al.,“Anti−CD20Therapy in Patients with Rheumatoid Arthritis”,Arthritis&Rheumatism,Vol.58,No.6,1566−1575(2008)。
17.Kajstura,J.et al.,“Myocite Turnover in the Aging Human Heart”,Circ. Res.,Vol.107(11),1374−86,(2010)。
18.de Groot,K.et al.,“Vascular Endothelial Damage and Repair in Antineutrophil Cytoplasmic Antibody−Associated Vasculitis”,Arthritis and Rheumatism,Vol.56(11),3847,3847(2007)。
19.Manesso,E.et al.,“Dynamics of β−Cell Turnover:Evidence for β−Cell Turnover and Regeneration from Sources of β−Cells other than β−cell Replication in the HIP Rat”,Am.J.Physiol.Endocrinol.Metab.,Vol.297,E323,E324(2009)。
20.Kirstein,M.et al.,“Receptor−specific Induction of Insulin−like Growth Factor I in Human Monocytes by Advanced Glycosylation End Product−modified Proteins”,J.Clin.Invest.,Vol.90,439,439−440(1992)。
21.Murphy,J.F.,“Trends in cancer immunotherapy”,Clinical Medical Insights:Oncology,Vol.14(4),67−80(2010)。
22.Virella,G.et al.,“Autoimmune Response to Advanced Glycosylation End−Products of Human LDL”,Journal of Lipid Research,Vol.44,487−493(2003)。
23.Ameli,S.et al.,“Effect of Immunization With Homologous LDL and Oxidized LDL on Early Atherosclerosis in Hypercholesterolemic Rabbits”,Arteriosclerosis,Thrombosis,and Vascular Biology,Vol.16,1074(1996)。
24.“Sarcopenia”、en.wikipedia.org/wiki/Sarcopeniaでオンライン入手可能(2014年11月14日)。
25.“What is sarcopenia?”、www.iofbonehealth.org/what−sarcopeniaでオンライン入手可能(2014年)。
26.Blahd,W.,“Sarcopenia with aging”、www.webmd.com/healthy−aging/sarcopenia−with−agingでオンライン入手可能(2014年8月3日)。
27.“Keyhole limpet hemocyanin”、en.wikipedia.org/wiki/Keyhole_limpet_hemocyaninでオンライン入手可能(2014年4月18日)。
28.“CML−BSA Product Data Sheet”、www.cellbiolabs.com/sites/default/files/STA−314−cml−bsa.pdfでオンライン入手可能(2010年)。
29.“CML(N−epsilon−(Carboxymethyl)Lysine)Assays and Reagents、www.cellbiolabs.com/cml−assaysでオンライン入手可能(2014年12月15日アクセス)。
30.Cruz−Jentoft,A.J.et al.,“Sarcopenia:European consensus on definition and diagnosis”,Age and Ageing,Vol.39,pp.412−423(April13,2010)。
31.Rolland,Y.et al.,“Sarcopenia:its assessment,etiology,pathogenesis,consequences and future perspectives”,J.Nutr.Health Aging,Vol.12(7),pp.433−450(2008)。
32.Mera,K.et al.,“An autoantibody against Nε−(carboxyethyl)lysine(CEL):Possible involvement in the removal of CEL−modified proteins by macrophages”,Biochemical and Biophysical Research Communications,Vol.407,pp.420−425(March12,2011)。
33.Reddy,S.et al.,“Nε−(carboxymethyl)lysine is a dominant advanced glycation end product(AGE)antigen in tissue proteins”,Biochemistry,Vol.34,pp.10872−10878(August1,1995)。
34.Naylor,R.M.et al.,“Senescent cells:a novel therapeutic target for aging and age−related diseases”,Clinical Pharmacology&Therapeutics,Vol.93(1),pp.105−116(December5,2012)。
35.Katcher,H.L.,“Studies that shed new light on aging”,Biochemistry(Moscow),Vol.78(9),pp.1061−1070(2013)。
36.Ahmed,E.K.et al.,“Protein Modification and Replicative Senescence of WI−38Human Embryonic Fibroblasts”,Aging Cells,Vol.9,252,260(2010)。
37.Vlassara,H.et al.,“Advanced Glycosylation Endproducts on Erythrocyte Cell Surface Induce Receptor−Mediated Phagocytosis by Macrophages”,J.Exp.Med.,Vol.166,539,545(1987)。
38.Fielding,R.A.,et al.,“Sarcopenia:an undiagnosed condition in older adults.Current consensus definition:prevalence,etiology,and consequences”,Journal of the American Medical Directors Association,Vol.12(4),pp.249−256(May2011)。
39.Maass,D.R.et al.,“Alpaca(Lama pacos)as a convenient source of recombinant camelid heavy chain antibodies(VHHs)”,Journal of Immunological Methods,Vol.324,No.1−2,pp.13−25(July31,2007)。
40.Strietzel,C.J.et al.,“In vitro functional characterization of feline IgGs”,Veterinary Immunology and Immunopathology,Vol.158,pp.214−223(2014)。
41.Patel,M.et al.,“Sequence of the dog immunoglobulin alpha and epsilon constant region genes”,Immunogenetics,Vol.41,pp.282−286(1995)。
42.Wagner,B.et al.,“The complete map of the Ig heavy chain constant gene region reveals evidence for seven IgG isotypes and for IgD in the horse”,The Journal of Immunology,Vol.173,pp.3230−3242(2004)。
43.Hamers−Casterman,C.et al.,“Naturally occurring antibodies devoid of light chains”,Nature,Vol.363,pp. 446−448(June3,1993)。
44.De Genst,E.et al.,“Antibody repertoire development in camelids”,Developmental&Comparative Immunology,Vol.30,pp.187−198(2005年7月11日オンライン入手可能)。
45.Griffin,L.M.et al.,“Analysis of heavy and light chain sequences of conventional camelid antibodies from Camelus dromedarius and Camelus bactrianus species”,Journal of Immunological Methods,Vol.405,pp.35−46(2014年1月18日オンライン入手可能)。
46.Nguyen,V.K.et al.,“Camel heavy−chain antibodies:diverse germline VHH and specific mechanisms enlarge the antigen−binding repertoire”,The European Molecular Biology Organization Journal,Vol.19,No,5,pp.921−930(2000)。
47.Muyldermans,S.et al.,“Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains”,Protein Engineering,Vol.7,No.9,pp.1129−1135(1994)。
Claims (17)
- 対象における転移性がんの治療、及び/またはがん転移の予防における使用のための、抗AGE抗体を含む組成物であって、前記抗AGE抗体が、カルボキシメチルリジン修飾タンパク質に結合する、前記組成物。
- 薬学的に許容される担体を更に含む、請求項1に記載の、使用のための組成物。
- 対象が、ヒト、マウス、ラット、ヤギ、ヒツジ、ウシ、ウマ、イヌ、及びネコからなる群から選択される、請求項1又は2に記載の、使用のための組成物。
- 対象が、ヒトである、請求項1〜3のいずれかに記載の、使用のための組成物。
- 抗AGE抗体が、ヒト、ネコ、イヌ、ウマ、ラクダ、アルパカ、ウシ、ヒツジ、及びヤギからなる群から選択される種に対して非免疫原性である、請求項1〜4のいずれかに記載の、使用のための組成物。
- 対象が、転移性がんを有する、請求項1〜5のいずれかに記載の、使用のための組成物。
- 請求項1〜5のいずれかに記載の、がん転移の予防における使用のための組成物であって、対象が、転移性がんを有さない、前記組成物。
- 単位投与量形態である、請求項1〜7のいずれかに記載の、使用のための組成物。
- (a)対象がヒトであり、
(b)抗AGE抗体が、ヒト、ネコ、イヌ、ウマ、ラクダ、アルパカ、ウシ、ヒツジ、及びヤギからなる群から選択される種に対して非免疫原性であり、
(c)前記対象が転移性がんを有し、かつ
(d)組成物が、単位投与量形態である、
請求項1〜5のいずれかに記載の、使用のための組成物。 - 複数回投与量形態(multidosage form)である、請求項1〜9のいずれかに記載の、使用のための組成物。
- 無菌である、請求項1〜10のいずれかに記載の、使用のための組成物。
- 抗AGE抗体が、AGE修飾を発現する転移性がん細胞に結合する、請求項1〜11のいずれかに記載の、使用のための組成物。
- 抗AGE抗体が、AGE修飾を発現する循環細胞に結合する、請求項1〜12のいずれかに記載の、使用のための組成物。
- 対象が、妊娠している、請求項1〜13のいずれかに記載の、使用のための組成物。
- 対象が、以前に癌性悪液質と診断されている、請求項1〜14のいずれかに記載の、使用のための組成物。
- 対象が、免疫不全である、請求項1〜15のいずれかに記載の、使用のための組成物。
- 転移性がんが、転移性乳がんである、請求項1〜16のいずれかに記載の使用のための組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662297744P | 2016-02-19 | 2016-02-19 | |
US62/297,744 | 2016-02-19 | ||
US201662425495P | 2016-11-22 | 2016-11-22 | |
US62/425,495 | 2016-11-22 | ||
PCT/US2017/018185 WO2017143073A1 (en) | 2016-02-19 | 2017-02-16 | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020106264A Division JP6811887B2 (ja) | 2016-02-19 | 2020-06-19 | 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019511469A JP2019511469A (ja) | 2019-04-25 |
JP2019511469A5 JP2019511469A5 (ja) | 2020-03-26 |
JP6722293B2 true JP6722293B2 (ja) | 2020-07-15 |
Family
ID=58191665
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018543120A Active JP6722293B2 (ja) | 2016-02-19 | 2017-02-16 | 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 |
JP2020106264A Active JP6811887B2 (ja) | 2016-02-19 | 2020-06-19 | 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020106264A Active JP6811887B2 (ja) | 2016-02-19 | 2020-06-19 | 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US11833202B2 (ja) |
EP (3) | EP4067386A1 (ja) |
JP (2) | JP6722293B2 (ja) |
KR (2) | KR102536017B1 (ja) |
CN (1) | CN109071675A (ja) |
AU (1) | AU2017219749B2 (ja) |
CA (1) | CA3021150C (ja) |
DK (2) | DK3337829T3 (ja) |
ES (2) | ES2770787T3 (ja) |
HK (1) | HK1256931A1 (ja) |
HU (2) | HUE047922T2 (ja) |
IL (2) | IL261006B (ja) |
MX (2) | MX2018009988A (ja) |
PL (1) | PL3337829T3 (ja) |
PT (1) | PT3337829T (ja) |
RU (1) | RU2728964C2 (ja) |
WO (1) | WO2017143073A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011521009A (ja) | 2008-05-23 | 2011-07-21 | シワ コーポレイション | 再生を促進させる方法、組成物及び装置 |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
RU2721568C2 (ru) | 2014-09-19 | 2020-05-20 | Сива Корпорейшн | Анти-age антитела для лечения воспаления и аутоиммунных нарушений |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
WO2018191718A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
EP4067386A1 (en) | 2016-02-19 | 2022-10-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
EP3443007A1 (en) | 2016-04-15 | 2019-02-20 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US20200150131A1 (en) | 2017-05-04 | 2020-05-14 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
US20220175916A1 (en) * | 2018-07-23 | 2022-06-09 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
US20210253739A1 (en) | 2018-08-23 | 2021-08-19 | Siwa Corporation | Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells |
JP2023524098A (ja) | 2020-05-01 | 2023-06-08 | シワ コーポレーション | 感染症を治療する方法 |
WO2022125776A2 (en) | 2020-12-09 | 2022-06-16 | Siwa Corporation | Methods and compositions for treating kidney diseases |
WO2023023654A1 (en) | 2021-08-20 | 2023-02-23 | Siwa Corporation | Methods and compositions for treating fibrotic diseases |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US5811075A (en) | 1984-03-19 | 1998-09-22 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
US4900747A (en) | 1984-03-19 | 1990-02-13 | The Rockefeller University | Method and agents for removing advanced glycosylation endproducts |
JP2644767B2 (ja) | 1986-09-12 | 1997-08-25 | ザ ロックフェラー ユニバーシティ | 後生的なグリコシル化最終産物を除去する為の方法及び薬剤 |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IN172208B (ja) | 1990-04-02 | 1993-05-01 | Sint Sa | |
US20080063603A1 (en) | 1990-04-02 | 2008-03-13 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US20040208826A1 (en) | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
US6372249B1 (en) | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
CA2126080A1 (en) | 1991-12-20 | 1993-07-08 | Jean-Yves Chapelon | Ultrasound therapy apparatus delivering ultrasound waves having thermal and cavitation effects |
WO1994000592A1 (en) | 1992-06-26 | 1994-01-06 | Exocell, Inc. | Monoclonal antibodies against glycated low density lipoprotein |
US5620479A (en) | 1992-11-13 | 1997-04-15 | The Regents Of The University Of California | Method and apparatus for thermal therapy of tumors |
US5518720A (en) | 1992-12-30 | 1996-05-21 | Exocell, Inc. | Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
US5744300A (en) | 1993-03-24 | 1998-04-28 | Geron Corporation | Methods and reagents for the identification and regulation of senescence-related genes |
CA2160909A1 (en) | 1993-04-28 | 1994-11-10 | Hagan Bayley | Cell-targeted lytic pore-forming agents |
US6410598B1 (en) | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US5935927A (en) | 1994-02-03 | 1999-08-10 | The Picower Institute For Medical Research | Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts |
US5744318A (en) | 1994-12-30 | 1998-04-28 | Alteon Inc. | Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples |
US5892000A (en) | 1994-12-30 | 1999-04-06 | Alteon Inc. | Monoclonal antibodies specific for advanced glycosylation endproducts in biological samples |
US6176842B1 (en) | 1995-03-08 | 2001-01-23 | Ekos Corporation | Ultrasound assembly for use with light activated drugs |
AU6907496A (en) | 1995-08-25 | 1997-03-19 | Case Western Reserve University | Process for detecting pentosidine and for assessing the biological age of a biological sample |
US5620409A (en) | 1995-09-15 | 1997-04-15 | The Research Foundation Of State University Of New York | Method for inhibiting clot formation |
JP3579549B2 (ja) | 1995-10-24 | 2004-10-20 | 株式会社トクヤマ | 糖尿病または糖尿病合併症用マーカーとしての使用 |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US5664570A (en) | 1996-02-20 | 1997-09-09 | Svc | Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body |
US5908925A (en) | 1996-06-27 | 1999-06-01 | Exocell, Inc. | Genetically engineered immunoglobulins with specificity for glycated albumin |
US5984882A (en) | 1996-08-19 | 1999-11-16 | Angiosonics Inc. | Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6245318B1 (en) | 1997-05-27 | 2001-06-12 | Mallinckrodt Inc. | Selectively binding ultrasound contrast agents |
US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
JP2001512698A (ja) | 1997-08-08 | 2001-08-28 | ユニバーシティ オブ ワシントン | 新規な老化因子遺伝子p23の単離 |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
US6896659B2 (en) | 1998-02-06 | 2005-05-24 | Point Biomedical Corporation | Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility |
JP4016304B2 (ja) | 1998-02-26 | 2007-12-05 | 日本油脂株式会社 | モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法 |
AU4556699A (en) | 1998-06-09 | 1999-12-30 | Alteon Inc. | Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples |
US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
ES2299267T3 (es) | 1998-10-06 | 2008-05-16 | The Trustees Of Columbia University In The City Of New York | Nueva proteina extracelular ligante de rage (en-rage) y sus usos. |
US6309355B1 (en) | 1998-12-22 | 2001-10-30 | The Regents Of The University Of Michigan | Method and assembly for performing ultrasound surgery using cavitation |
WO2000051637A1 (en) | 1999-03-02 | 2000-09-08 | Centocor, Inc. | ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
US6067859A (en) | 1999-03-04 | 2000-05-30 | The Board Of Regents, The University Of Texas System | Optical stretcher |
AT500848B1 (de) | 1999-06-25 | 2008-01-15 | Genentech Inc | Humanisierte anti-erbb2-antikörper |
AU6766800A (en) | 1999-08-13 | 2001-03-13 | Trustees Of Columbia University In The City Of New York, The | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
WO2001018060A1 (fr) | 1999-09-08 | 2001-03-15 | Toray Industries, Inc. | Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique |
US6853864B2 (en) | 2000-02-02 | 2005-02-08 | Catholic University Of America, The | Use of electromagnetic fields in cancer and other therapies |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2001089584A2 (en) | 2000-05-23 | 2001-11-29 | Amersham Health As | Contrast agents |
NO312338B1 (no) | 2000-08-25 | 2002-04-29 | Gunnar Myhr | Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme |
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CN2445326Y (zh) | 2000-10-09 | 2001-08-29 | 刘永详 | 测定被糖化蛋白的免疫分析装置 |
US6676963B1 (en) | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US6821274B2 (en) | 2001-03-07 | 2004-11-23 | Gendel Ltd. | Ultrasound therapy for selective cell ablation |
US7481781B2 (en) | 2000-11-17 | 2009-01-27 | Gendel Limited | Ultrasound therapy |
IL156439A0 (en) | 2001-01-03 | 2004-01-04 | Ultrashape Ltd | Non-invasive ultrasonic body contouring |
US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
ATE283481T1 (de) | 2001-03-22 | 2004-12-15 | Hoffmann La Roche | Verfahren zum auffinden von reagenzien und festphasenkomponenten in spezifischen bindungsassays, frei von fortgeschrittenen glykosylierungsendprodukten |
US20040210042A1 (en) | 2001-07-19 | 2004-10-21 | Tsuchida Jun-Ichi | Polypeptides relating to signal transfer of advanced glycation end product receptor |
JP4012722B2 (ja) | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
WO2004011460A2 (en) | 2002-07-24 | 2004-02-05 | Qlt, Inc. | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
US20060140933A1 (en) | 2002-08-16 | 2006-06-29 | Wyeth And Imperial College Innovations Limited | Compositions and methods for treating rage-associated disorders |
US20070128117A1 (en) | 2003-02-04 | 2007-06-07 | Bracco International B.V. | Ultrasound contrast agents and process for the preparation thereof |
EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
WO2004079368A2 (en) | 2003-03-08 | 2004-09-16 | Auvation Ltd | Markers for colorectal cancer |
EP1648314A2 (de) | 2003-07-31 | 2006-04-26 | Woodwelding AG | Verfahren und vorrichtung zur förderung der geweberegeneration an wundflächen |
US7358226B2 (en) | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
WO2005070472A2 (en) | 2004-01-20 | 2005-08-04 | Sunnybrook And Women's College Health Sciences Centre, | High frequency ultrasound imaging using contrast agents |
CA2557837A1 (en) | 2004-02-17 | 2005-09-01 | Dynamis Therapeutics, Inc. | Fructoseamine 3 kinase and the formation of collagen and elastin |
US7470521B2 (en) * | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
EA012082B1 (ru) | 2004-08-03 | 2009-08-28 | Транстек Фарма, Инк. | Белки слияния на основе rage и способы их использования |
GB0422525D0 (en) | 2004-10-11 | 2004-11-10 | Luebcke Peter | Dermatological compositions and methods |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
US7846100B2 (en) | 2005-03-03 | 2010-12-07 | Bracco International Bv | Medical imaging system based on a targeted contrast agent |
JP2006249015A (ja) | 2005-03-11 | 2006-09-21 | Mochida Pharmaceut Co Ltd | 細胞老化抑制剤 |
KR20070094950A (ko) | 2005-04-05 | 2007-09-27 | 가부시끼가이샤 제이엠에스 | 3,4-dge에서 유래하는 age에 특이적으로 반응하는항체 |
JP2006288864A (ja) | 2005-04-13 | 2006-10-26 | Padoru:Kk | 外科手術用の骨固定具 |
US20070225242A1 (en) | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20070059247A1 (en) | 2005-08-30 | 2007-03-15 | Lindner Jonathan R | Deposit contrast agents and related methods thereof |
US20070065415A1 (en) | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
US20070083120A1 (en) | 2005-09-22 | 2007-04-12 | Cain Charles A | Pulsed cavitational ultrasound therapy |
US20070078290A1 (en) | 2005-09-30 | 2007-04-05 | Esenaliev Rinat O | Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues |
US7766833B2 (en) | 2005-11-23 | 2010-08-03 | General Electric Company | Ablation array having independently activated ablation elements |
JP4779115B2 (ja) | 2005-12-16 | 2011-09-28 | 国立大学法人東北大学 | 早期肺癌の術後予後検査方法 |
WO2007098186A2 (en) | 2006-02-22 | 2007-08-30 | Novavax, Inc. | Adjuvant and vaccine compositions |
WO2007100770A2 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
US20100249038A1 (en) * | 2007-06-12 | 2010-09-30 | Board Of Regents, University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
CA2690056C (en) | 2007-06-14 | 2017-08-29 | Galactica Pharmaceuticals, Inc. | Rage fusion proteins |
JP2007277263A (ja) | 2007-07-13 | 2007-10-25 | Transgenic Inc | カルボキシメチル化タンパク質に対する抗体 |
WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
US7751057B2 (en) | 2008-01-18 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Magnetomotive optical coherence tomography |
DE102008009461A1 (de) | 2008-02-15 | 2009-08-20 | Beiersdorf Ag | Verfahren zur Reduzierung der Zeichen der Hautalterung |
ES2579554T3 (es) * | 2008-05-09 | 2016-08-12 | Abbvie Deutschland Gmbh & Co Kg | Anticuerpos para el receptor de productos terminales de glicación avanzada (RAGE) y usos de los mismos |
JP2011521009A (ja) | 2008-05-23 | 2011-07-21 | シワ コーポレイション | 再生を促進させる方法、組成物及び装置 |
JP5229473B2 (ja) | 2008-06-04 | 2013-07-03 | 財団法人ヒューマンサイエンス振興財団 | 超音波医療装置 |
WO2010005531A2 (en) | 2008-06-30 | 2010-01-14 | The Johns Hopkins University | Methods for the detection of advanced glycation endproducts and markers for disease |
EP2399934B1 (en) | 2009-02-20 | 2017-09-06 | The University of Tokyo | Novel monoclonal antibody, and use thereof |
WO2010132580A2 (en) | 2009-05-12 | 2010-11-18 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
WO2011035104A1 (en) | 2009-09-17 | 2011-03-24 | Sanuwave, Inc. | Methods and devices for cleaning and sterilization with shock waves |
US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
EP2493486A1 (en) | 2009-10-30 | 2012-09-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
WO2011101039A1 (en) | 2010-02-22 | 2011-08-25 | Universite Pierre Et Marie Curie (Paris 6) | Apparatus for the treatment of brain affections and method implementing thereof |
US9662347B2 (en) | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
EP3511017A1 (en) | 2010-09-27 | 2019-07-17 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
WO2012135616A1 (en) | 2011-03-31 | 2012-10-04 | Siwa Corporation | Vaccination against advanced glycation end-products |
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
WO2013009784A2 (en) | 2011-07-10 | 2013-01-17 | Guided Therapy Systems, Llc | Systems and method for accelerating healing of implanted material and/or native tissue |
US8954155B2 (en) | 2011-09-19 | 2015-02-10 | Biotalk Technologies Inc | Apparatus and method for rejuvenating skin |
US9422365B2 (en) | 2011-09-23 | 2016-08-23 | Julius-Maximilians-Universität Würzburg | Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site |
US20140322216A1 (en) | 2011-11-08 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
KR101939401B1 (ko) | 2011-11-10 | 2019-01-16 | 가천대학교 산학협력단 | 단핵식세포계 세포의 age-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물 |
AU2012352177A1 (en) | 2011-12-13 | 2014-07-10 | Buck Institute For Research On Aging | Methods for improving medical therapies |
EA031069B1 (ru) | 2012-02-17 | 2018-11-30 | Сиэтл Дженетикс, Инк. | АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
US20130288980A1 (en) | 2012-04-02 | 2013-10-31 | Buck Institute For Research On Aging | Targeting senescent and cancer cells for selective killing by interference with foxo4 |
US10379026B2 (en) | 2012-08-29 | 2019-08-13 | Inguran, Llc | Cell processing using magnetic particles |
KR101520336B1 (ko) | 2012-11-30 | 2015-05-14 | 전남대학교산학협력단 | 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물 |
WO2014089124A1 (en) | 2012-12-03 | 2014-06-12 | Cenexys, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
EP2742935A1 (en) | 2012-12-14 | 2014-06-18 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | SERF2 for the treatment of atrophy and for increasing cell growth |
US20160017021A1 (en) | 2013-03-06 | 2016-01-21 | Protalix Ltd. | TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME |
US20140257262A1 (en) | 2013-03-11 | 2014-09-11 | Alexandre Carpentier | Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same |
US20160068577A1 (en) | 2013-03-12 | 2016-03-10 | Molecular Templates, Inc. | Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types |
JP6549560B2 (ja) | 2013-05-14 | 2019-07-24 | 上海 ハイチャーム インコーポレーテッドShanghai Hycharm Inc. | 低免疫原性タンパク質に対するエピトープワクチンおよびその製造方法と使用 |
EP3082875B1 (en) | 2013-12-16 | 2020-11-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
EP3094350B1 (en) | 2014-01-15 | 2020-03-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cartilage targeting agents and their use |
US10099027B2 (en) | 2014-01-24 | 2018-10-16 | Cole Research & Design | Oral suction device |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
SG10201805670QA (en) | 2014-01-28 | 2018-08-30 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
US10238742B2 (en) | 2014-06-25 | 2019-03-26 | Yale University | Cell penetrating nucleolytic antibody based cancer therapy |
RU2721568C2 (ru) | 2014-09-19 | 2020-05-20 | Сива Корпорейшн | Анти-age антитела для лечения воспаления и аутоиммунных нарушений |
US20170240632A1 (en) * | 2014-10-16 | 2017-08-24 | The Broad Institute Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
WO2017065837A1 (en) * | 2015-10-13 | 2017-04-20 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
EP4067386A1 (en) | 2016-02-19 | 2022-10-05 | Siwa Corporation | Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age) |
WO2018191718A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
US10981021B2 (en) | 2016-03-11 | 2021-04-20 | Carthera | Method for transiently disrupting a region of the blood-brain barrier of a human |
EP3443007A1 (en) | 2016-04-15 | 2019-02-20 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
US10172684B2 (en) | 2016-04-29 | 2019-01-08 | Ethicon Llc | Lifecycle monitoring features for surgical instrument |
EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
RU2617313C1 (ru) | 2016-07-18 | 2017-04-24 | Государственное автономное учреждение здравоохранения Свердловской области "Центр специализированных видов медицинской помощи "Институт медицинских клеточных технологий" | Способ определения биологического возраста у мужчин |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US20200150131A1 (en) | 2017-05-04 | 2020-05-14 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
US20220175916A1 (en) | 2018-07-23 | 2022-06-09 | Siwa Corporation | Methods and compositions for treating chronic effects of radiation and chemical exposure |
WO2020036973A1 (en) | 2018-08-14 | 2020-02-20 | Imel Biotherapeutics, Inc. | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy |
US20210253739A1 (en) | 2018-08-23 | 2021-08-19 | Siwa Corporation | Anticarboxymethyl lysine antibodies and ultrasound for removing age-modified cells |
JP2023524098A (ja) | 2020-05-01 | 2023-06-08 | シワ コーポレーション | 感染症を治療する方法 |
WO2021247397A2 (en) | 2020-06-04 | 2021-12-09 | Siwa Corporation | Methods and compositions for enhancing the immune system |
WO2022093195A1 (en) | 2020-10-27 | 2022-05-05 | Siwa Corporation | Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens |
WO2023023654A1 (en) | 2021-08-20 | 2023-02-23 | Siwa Corporation | Methods and compositions for treating fibrotic diseases |
WO2023177390A1 (en) | 2022-03-14 | 2023-09-21 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer |
-
2017
- 2017-02-16 EP EP22157145.8A patent/EP4067386A1/en active Pending
- 2017-02-16 HU HUE17708098A patent/HUE047922T2/hu unknown
- 2017-02-16 RU RU2018132998A patent/RU2728964C2/ru active
- 2017-02-16 PL PL17708098T patent/PL3337829T3/pl unknown
- 2017-02-16 CN CN201780024206.XA patent/CN109071675A/zh active Pending
- 2017-02-16 WO PCT/US2017/018185 patent/WO2017143073A1/en active Application Filing
- 2017-02-16 AU AU2017219749A patent/AU2017219749B2/en active Active
- 2017-02-16 PT PT177080983T patent/PT3337829T/pt unknown
- 2017-02-16 MX MX2018009988A patent/MX2018009988A/es unknown
- 2017-02-16 EP EP17708098.3A patent/EP3337829B1/en active Active
- 2017-02-16 ES ES17708098T patent/ES2770787T3/es active Active
- 2017-02-16 ES ES19210193T patent/ES2912064T3/es active Active
- 2017-02-16 DK DK17708098.3T patent/DK3337829T3/da active
- 2017-02-16 EP EP19210193.9A patent/EP3677598B1/en active Active
- 2017-02-16 HU HUE19210193A patent/HUE058854T2/hu unknown
- 2017-02-16 KR KR1020187026021A patent/KR102536017B1/ko active IP Right Grant
- 2017-02-16 JP JP2018543120A patent/JP6722293B2/ja active Active
- 2017-02-16 CA CA3021150A patent/CA3021150C/en active Active
- 2017-02-16 US US16/077,713 patent/US11833202B2/en active Active
- 2017-02-16 KR KR1020237016986A patent/KR20230074837A/ko not_active Application Discontinuation
- 2017-02-16 DK DK19210193.9T patent/DK3677598T3/da active
-
2018
- 2018-08-06 IL IL261006A patent/IL261006B/en active IP Right Grant
- 2018-08-17 MX MX2022014630A patent/MX2022014630A/es unknown
- 2018-12-13 HK HK18116058.5A patent/HK1256931A1/zh unknown
-
2020
- 2020-06-19 JP JP2020106264A patent/JP6811887B2/ja active Active
-
2021
- 2021-06-06 IL IL283726A patent/IL283726A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6722293B2 (ja) | 終末糖化産物(age)に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 | |
US11873345B2 (en) | Product and method for treating sarcopenia | |
US11542324B2 (en) | Humanized monoclonal advanced glycation end-product antibody | |
RU2766209C2 (ru) | Антитела к age и способы их применения | |
US11958900B2 (en) | Anti-age antibodies for treating neurodegenerative disorders | |
US10858449B1 (en) | Methods and compositions for treating osteoarthritis | |
US10889634B2 (en) | Anti-age antibodies and methods of use thereof | |
US20210253737A1 (en) | Methods and compositions for treating disease-related cachexia | |
WO2023177390A1 (en) | Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer | |
AU2018251183A1 (en) | Humanized monoclonal advanced glycation end-product antibody | |
EA039745B1 (ru) | Новые соединения, способные противодействовать повреждению -клеток, индуцируемому островковым амилоидным полипептидом, и нарушению толерантности к глюкозе |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200214 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200214 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200214 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200415 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200525 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200619 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6722293 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |